200
Participants
Start Date
December 15, 2020
Primary Completion Date
November 30, 2025
Study Completion Date
February 28, 2026
ERAS-601
Administered orally
Cetuximab
Administered via intravenous infusion
Pembrolizumab
Administered via intravenous infusion
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
University of North Carolina, Chapel Hill
Sarah Cannon Research Institute (Florida Cancer Specialists), Sarasota
University of Alabama at Birmingham, Birmingham
Sarah Cannon Research Institute (Tennessee Oncology), Nashville
University of Cincinnati, Cincinnati
Washington University, St Louis
Mary Crowley Cancer Research, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Cancer Centers of Nevada, Henderson
Massachusetts General Hospital, Boston
Peter MacCallum Cancer Centre, Melbourne
Linear Clinical Research, Perth
Erasca, Inc.
INDUSTRY